Thank you, Madam Chair.
Thank you for being here with us.
Dr. Carleton, thank you for being back with us again. Like Mr. Thibault, I find that the approach that you are presenting to committee members is interesting. I would like to go back to the comments you made in your preliminary remarks. As I understand it, the vast majority, if not all, of the medications on our shelves as a result of our pre-market process are safe. If the medications produce adverse reactions, they are, in many cases, because of the presence of genes in some individuals that are not found in others, on whom the medication has no undesirable effects at all.
If that is the case—you can correct me if I am wrong—are we not avoiding the essential if we do not consider the genetic aspects of the entire post-market process?